Rationale, design, and synthesis of novel phenyl imidazoles as opioid receptor agonists for gastrointestinal disorders

Journal of Medicinal Chemistry

Volumn 47, Issue 21, 2004, Pages 5009-5020

  Breslin, Henry J ^a   Miskowski, Tamara A ^a   Rafferty, Bryan M ^a   Coutinho, Santosh V ^a   Palmer, Jeffrey M ^a   Wallace, Nathaniel H ^a   Schneider, Craig R ^a   Kimball, Edward S ^a   Zhang, Sui Po ^a   Li, Jian ^a   Colburn, Raymond W ^a   Stone, Dennis J ^a   Martinez, Rebecca P ^a   He, Wei ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 3 (4 HYDROXYPHENYL) 1 [3 (5 PHENYL 1H IMIDAZOL 2 YL) 3,4 DIHYDRO 1H ISOQUINOLIN 2 YL]PROPAN 1 ONE TRIFLUOROACETATE; DELTA OPIATE RECEPTOR; FENTANYL; IMIDAZOLE DERIVATIVE; KAPPA OPIATE RECEPTOR; LOPERAMIDE; MORPHINE; MU OPIATE RECEPTOR; NALOXONE; OPIATE AGONIST; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ANALGESIC ACTIVITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; COLON MOTILITY; CONTROLLED STUDY; DEFECATION; DOSE RESPONSE; DRUG CONFORMATION; DRUG INDICATION; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; RAT;

ABDOMINAL MUSCLES; ANALGESICS; ANIMALS; CHO CELLS; CRICETINAE; GASTROINTESTINAL DISEASES; GASTROINTESTINAL MOTILITY; IMIDAZOLES; INJECTIONS, INTRAVENTRICULAR; INJECTIONS, SUBCUTANEOUS; MALE; MICE; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MUSCLE CONTRACTION; PAIN MEASUREMENT; RATS; RATS, WISTAR; RECEPTORS, OPIOID; RECEPTORS, OPIOID, DELTA; RECEPTORS, OPIOID, MU; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 4744359316     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm030548r     Document Type: Article

References (27)

1. (a) Fries, D. S. Analgesics. In Principles of Medicinal Chemistry, 4th ed.; Foye, W. O., Lemke, T. L., Williams, D. A., Eds.; Willimams and Wilkins: Baltimore, MD, 1995; pp 247-269;
2. (b) Aldrich, J. V. "Analgesics" Burger's Medicinal Chemistry and Drug Discovery, 5th ed., Volume 3: Therapeutic Agents, John Wiley & Sons: New York, 1996; pp 321-441.
3. Riviere, J. M.; Junien, J.-L. Opioid Receptors: Targets for New Gastrointestinal Drug Development. In Drug Development: Molecular Targets for GI Diseases; Gaginella, T. S., Guglietta, A., Eds.; Humana Press Inc., Totowa, NJ, pp 203-238.
4. Hughes, J.; Smith, T. W.; Kosterlitz, H. W.; Fothergill, L. A.; Morgan, B. A.; Morris, H. R. Identification of two related pentapeptides from the brain with potent opiate agonist activity. Nature (London) 1975, 258 (5536), 577-579.
5. Schiller P. W.; Weltrowska G.; Nguyen T. M.; Wilkes B. C.; Chung N. N.; Lemieux C. TIPP[psi]: a highly potent and stable pseudopeptide delta opioid receptor antagonist with extraordinary delta selectivity. J. Med. Chem. 1993, 36 (21), 3182-3187.
6. Schiller, P. New Use of Dipeptide Derivatives WO 98/28327, July 2, 1998.
7. Schiller, P. W.; Nguyen, T. M. D.; Weltrowska, G.; Wilkes, B. C.; Marsden, B. J.; Lemieux, C.; Chung, N. N. Differential stereochemical requirements of μ vs δ opioid receptors for ligand binding and signal transduction: Development of a class of potent and highly δ-selective peptide antagonists. Proc. Natl. Acad. Sci. U.S.A. 1992, 89 (24), 11871-11875.
8. Marsden, B. J.; Nguyen, T.M-D; Schiller, P. W. Spontaneous degradation via diketopiperazine formation of peptides containing a tetrahydroisoquinoline- 3-carboxylic acid residue in the 2-position of the peptide sequence. Int. J. Pept. Protein Res. 1993, 41 (3), 313-316.
9. Rose, C.; Vargas, F.; Facchinetti, P.; Bourgeat, P.; Bambal, R. B.; Bishop, P. B.; Chan, S. M. T.; Moore, A. N. J.; Ganellin, C. R.; Schwartz, J.-C. Characterization and Inhibition of a Cholecystokinin-Inactivating Serine Peptidase. Nature 1996, 380, 403-409.
10. Breslin, H. J.; Miskowski, T. A.; Kukla, M. J.; Leister, W. H.; De Winter, H. L.; Gauthier, D. A.; Somers, M. V. F.; Peeters, D. C. G.; Roevens, P. W. M. Design, Synthesis, and Tripeptidyl Peptidase II Inhibitory Activity of a Novel Series of (S)-2,3-Dihydro-2-(4-alkyl-1H-imidazol-2-yl)-1H-indoles. J. Med. Chem. 2002, 45 (24), 5303-5310.
11. von Geldern, T. W.; Hutchins, C.; Rester, J. A.; Wu-Wong, J. R.; Chiou, W.; Dixon, D. B.; Opgenorth, T. J. Azole Endothelin Antagonists. I. A Receptor Model Explains an Unusual Structure-Activity Profile. J. Med. Chem. 1996, 39, 957-967.
12. Gordon, T. D.; Singh, J.; Hansen, P. E.; Morgan, B. A. Synthetic approaches to the 'Azole' peptide mimetics. Tetrahedron Lett. 1993, 1901-1904.
13. Byk, G.; Lelievre, Y.; Duchesne, M.; Clerc, F. F.; Scherman, D.; Guitton, J. D. Synthesis and conformational analysis of peptide inhibitors of farnesyltransferase. Bioorg. Med. Chem. 1997, 5 (1), 115-124.
14. Ross, M. Grimmett Imidazole and Benzimidazole Synthesis; Academic Press: San Diego, California; 1997; pp 151-165.
15. 2 7.67), based on the MVD assay. We found 4f to possess modest agonist activity based on the δ GTPγS OR assay. Balboni, G.; Salvadori, S.; Guerrini, R.; Bianchi, C.; Santagada, V.; Calliendo, G.; Bryant, S. D.; Lazarus, L. H. Opioid pseudopeptides containing heteroaromatic or heteroaliphatic nuclei. Peptides 2000, 21 (11), 1663-1671.
16. Schiller, P. W.; Nguyen, T. M. D.; Berezowska, I.; Weltrowska, G.; Schmidt, R.; Marsden, B. J.; Wilkes, B. C.; Lemieux, C.; Chung, N. N. The TIPP opioid peptide family: development of a new class of highly potent δ-receptor antagonists with extraordinary δ-selectivity. Pept. Chem. 1992, Proc. Jpn. Symp., 2nd, 1992, Meeting Date(Pub. 1993), 337-340.
17. Halgren, T. A. Merck molecular force field. J. Comput. Chem. 1996, 17, 490-642.
18. Balboni, G.; Salvadori, S.; Guerrini, R.; Negri, L.; Giannini, E.; Jinsmaa, Y.; Bryant, S. D.; Lazarus, L. H. Potent δ-opioid receptor agonists containing the Dmt-Tic pharmacophore. J. Med. Chem. 2002, 45, 5556-5563.
19. Bryant, S. D.; George, C.; Flippen-Anderson, J. L.; Deschamps J. R.; Salvadori, S.; Balboni, G.; Guerrini, R.; Lazarus, L. H. Crystal structure of dipeptides containing the Dmt-Tic pharmacophore. J. Med. Chem. 2002, 45, 5506-5513.
20. SYBYL, version 6.8.1, Tripos Inc. (1699 South Hanley Rd., St. Louis, MO 63144).
21. Guzman, A.; Quintero, C.; Muchowski, J. M. Alkylation of α-tert-butoxycarbonylamino ketone enolate anions. A useful synthesis of α-alkyl-α-amino ketones, 2-acylpyrrolidines, and 2-acylpiperidines. Can. J. Chem. 1991, 69 (12), 2059-2063.
22. Codd, E. E.; Shank, R. P.; Schupsky, J. J.; Raffa, R. B. Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: structural determinants and role in anti-nociception. J. Pharmacol. Exp. Ther. 1995, 274(3), 1263-1270.
23. Zhang, S.-P.; Wang, H.-Y.; Lovenberg, T. W.; Codd, E. E. Functional studies of bradykinin receptors in Chinese hamster ovary cells stably expressing the human B2 bradykinin receptor. International Immunopharmacology 2001, 1 (5), 955-965.
24. Collier, H. O.; Dinneen, L. C.; Johnson, C. A.; Schneider, C. The abdominal constriction response and its suppression by analgesic drugs in the mouse. Br. J. Pharmacol. 1868, 32 (2), 295-310.
25. Haley, T. J.; McCormick, W. G. Pharmacological effects produced by intracerebral injection of drugs in the conscious mouse. Br. J. Pharmacol. 1957, 12, 12-15.
26. Rush, B. D.; Ruwart, M. The role of accelerated colonic transit in prostaglandin-induced diarrhea and its inhibition by prostacyclin. Br. J. Pharmacol. 1984, 83, 157-159.
27. Coutinho, S. V.; Plotsky, P. M.; Sablad, M.; Miller, J. C.; Zhou, H.; Bayati, A. I.; McRoberts, J. A.; Mayer, E. A. Neonatal maternal separation alters stress-induced responses to viscerosomatic nociceptive stimuli in rat. Am. J. Physiol. Gastrointest. Liver Physiol. 2002, 282 (2), G307-G316.